Page last updated: 2024-11-07

wr 159412

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID100475
CHEMBL ID268089
MeSH IDM0075621

Synonyms (29)

Synonym
NSC305782 ,
51123-99-0
mls003115820 ,
nsc-305782
2, 6-[[3-(trifluoromethyl)phenyl]thio]-
NCI60_002591
NCIMECH_000537 ,
2,4-quinazolinediamine, 6-[[3-(trifluoromethyl)phenyl]thio]-
smr001831386
CHEMBL268089
wr-159412
6-[3-(trifluoromethyl)phenyl]sulfanylquinazoline-2,4-diamine
zal3kj3azc ,
2,4-quinazolinediamine, 6-((3-(trifluoromethyl)phenyl)thio)-
wr 159412
2,4-diamino-6-(5-trifluoromethylphenyl)thioquinazoline
unii-zal3kj3azc
nsc 305782
wr-159,412
6-((3-(trifluoromethyl)phenyl)thio)-2,4-quinazolinediamine
wr 159,412
CCG-35588
bdbm50404678
DTXSID00199145
6-{[3-(trifluoromethyl)phenyl]sulfanyl}-2,4-quinazolinediamine
2,4-diamino-6-(5-trifluoromethylphenyl)-thioquinazoline
6-((3-(trifluoromethyl)phenyl)thio)quinazoline-2,4-diamine
bfqqhtilcqzrgx-uhfffaoysa-n
6-{[3-(trifluoromethyl)phenyl]sulfanyl}quinazoline-2,4-diamine
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency11.22020.01846.806014.1254AID624417
USP1 protein, partialHomo sapiens (human)Potency19.95260.031637.5844354.8130AID743255
TDP1 proteinHomo sapiens (human)Potency5.24970.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency22.38720.00527.809829.0929AID588855
67.9K proteinVaccinia virusPotency6.04570.00018.4406100.0000AID720579; AID720580
IDH1Homo sapiens (human)Potency5.80480.005210.865235.4813AID686970
Guanine nucleotide-binding protein GHomo sapiens (human)Potency2.81841.995325.532750.1187AID624287
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency56.23413.981146.7448112.2020AID720708
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dihydrofolate reductaseRattus norvegicus (Norway rat)IC50 (µMol)0.03630.00060.35076.2000AID58160
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (48)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1144020Antimalarial activity against pyrimethamine-sensitive Plasmodium falciparum Vietnam Oak Knoll infected in Aotus trivirgatus owl monkey model assessed as cure from parasite infection at 0.6 mg/kg, po qd for 7 days relative to control1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID58164Concentration required for inhibition of rat liver dihydrofolate reductase (DHFR)1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Combined distance geometry analysis of dihydrofolate reductase inhibition by quinazolines and triazines.
AID1135018Antimalarial activity against chloroquine-resistant, pyrimethamine-sensitive Plasmodium falciparum Vietnam Oak Knoll in Aotus monkey assessed as dose required to >50% cures compound treated for 7 days1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID58160Inhibitory activity against dihydrofolate reductase of rat liver1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Inhibition of dihydrofolate reductase: structure-activity correlations of quinazolines based upon molecular shape analysis.
AID111801Antimalarial activity against Plasmodium berghei in mice (Mus musculus) by parenteral route and change in mean survival time in days was determined at 80 mg/kg subcutaneous dose; 5 cured at 60 days post infection1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antimalarial and antitumor effects of 2-amino-4-(hydrazino and hydroxyamino)-6-[(aryl)thio]quinazolines.
AID1143999Antimalarial activity against sporozoite-induced Plasmodium gallinaceum infected in white leghorn chicken assessed as disease cure from parasite infection at 40 mg/kg, sc administered 72 hrs after infection1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID56148Binding energy to Streptococcus faecium dihydrofolate reductase1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Quantitative structure-activity relationship by distance geometry: quinazolines as dihydrofolate reductase inhibitors.
AID1143993Antimalarial activity against sporozoite-induced Plasmodium gallinaceum infected in white leghorn chicken assessed as disease cure from parasite infection at 80 mg/kg, sc administered 72 hrs after infection1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID1146760Inhibition of Streptococcus faecium dihydrofolate reductase using dihydrofolate as substrate1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Quantitative structure-activity relationships of antimalarial and dihydrofolate reductase inhibition by quinazolines and 5-substituted benzyl-2,4-diaminopyrimidines.
AID56152Binding energy against Streptococcus faecium dihydrofolate reductase1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Quantitative structure-activity relationships by distance geometry: systematic analysis of dihydrofolate reductase inhibitors.
AID1145385Inhibition of liver dihydrofolate reductase (unknown origin)1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Inhibition of dihydrofolate reductase. Structure-activity correlations of quinazolines.
AID1143981Antimalarial activity against sporozoite-induced Plasmodium gallinaceum infected in white leghorn chicken assessed as disease cure from parasite infection at 320 mg/kg, sc administered 72 hrs after infection1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID1144004Antimalarial activity against sporozoite-induced Plasmodium gallinaceum infected in white leghorn chicken assessed as disease cure from parasite infection at 20 mg/kg, sc administered 72 hrs after infection1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID1144007Antimalarial activity against sporozoite-induced Plasmodium gallinaceum infected in white leghorn chicken assessed as increase in mean survival days of host at 10 mg/kg, sc administered 72 hrs after infection relative to control1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID1143943Antimalarial activity against Plasmodium berghei infected in mouse assessed as disease cure from parasite infection at 640 mg/kg, sc administered 72 hrs after infection1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID111798Antimalarial activity against Plasmodium berghei strain in mice (Mus musculus) by parentral route and change in mean survival time in days was determined at 640 mg/kg subcutaneous dose; 5 cured at 60 days postinfection1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antimalarial and antitumor effects of 2-amino-4-(hydrazino and hydroxyamino)-6-[(aryl)thio]quinazolines.
AID1143945Antimalarial activity against Plasmodium berghei infected in mouse assessed as disease cure from parasite infection at 160 mg/kg, sc administered 72 hrs after infection1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID1135017Antimalarial activity against chloroquine-sensitive, pyrimethamine-resistant Plasmodium falciparum Malayan Camp CH/Q infected in Aotus monkey assessed as dose required to >50% cures compound treated for 7 days1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1143947Antimalarial activity against Plasmodium berghei infected in mouse assessed as disease cure from parasite infection at 40 mg/kg, sc administered 72 hrs after infection1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID1144018Antimalarial activity against chloroquine-susceptible, pyrimethamine-resistant Plasmodium falciparum Malayan Camp infected in Aotus trivirgatus owl monkey model assessed as cure from parasite infection at >2.5 mg/kg, po qd for 7 days relative to control1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID111794Antimalarial activity against Plasmodium berghei in mice (Mus musculus) by parenteral route and change in mean survival time in days was determined at 40 mg/kg subcutaneous dose; 3 cured at 60 days post infection1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antimalarial and antitumor effects of 2-amino-4-(hydrazino and hydroxyamino)-6-[(aryl)thio]quinazolines.
AID1143937Antimalarial activity against Plasmodium berghei infected in mouse assessed as increase in mean survival days of host at 40 mg/kg, sc administered 72 hrs after infection relative to control1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID1144009Antimalarial activity against sporozoite-induced Plasmodium gallinaceum infected in white leghorn chicken assessed as disease cure from parasite infection at 10 mg/kg, sc administered 72 hrs after infection1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID1143946Antimalarial activity against Plasmodium berghei infected in mouse assessed as disease cure from parasite infection at 80 mg/kg, sc administered 72 hrs after infection1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID58159The concentration required to inhibit dihydrofolate reductase in rat liver1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
General distance geometry three-dimensional receptor model for diverse dihydrofolate reductase inhibitors.
AID1144017Antimalarial activity against chloroquine-susceptible, pyrimethamine-resistant Plasmodium falciparum Malayan Camp infected in Aotus trivirgatus owl monkey model assessed as cure from parasite infection at 0.39 to 5 mg/kg, po qd for 7 days relative to cont1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID1143941Antimalarial activity against Plasmodium berghei infected in mouse assessed as increase in mean survival days of host at 2.5 mg/kg, sc administered 72 hrs after infection relative to control1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID111803Antimalarial activity against Plasmodium berghei strain in mice (Mus musculus) by parentral route and change in mean survival time in days was determined at 160 mg/kg subcutaneous dose; 5 cured at 60 days postinfection1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antimalarial and antitumor effects of 2-amino-4-(hydrazino and hydroxyamino)-6-[(aryl)thio]quinazolines.
AID1143938Antimalarial activity against Plasmodium berghei infected in mouse assessed as increase in mean survival days of host at 20 mg/kg, sc administered 72 hrs after infection relative to control1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID1143956Antimalarial activity against trophozoite-induced Plasmodium gallinaceum infected in white leghorn chicken assessed as increase in mean survival days of host at 160 mg/kg, sc administered 72 hrs after infection relative to control1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID1143939Antimalarial activity against Plasmodium berghei infected in mouse assessed as increase in mean survival days of host at 10 mg/kg, sc administered 72 hrs after infection relative to control1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID1143944Antimalarial activity against Plasmodium berghei infected in mouse assessed as disease cure from parasite infection at 320 mg/kg, sc administered 72 hrs after infection1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID1143942Antimalarial activity against Plasmodium berghei infected in mouse assessed as increase in mean survival days of host at 1.25 mg/kg, sc administered 72 hrs after infection relative to control1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID1144019Antimalarial activity against pyrimethamine-sensitive Plasmodium falciparum Vietnam Oak Knoll infected in Aotus trivirgatus owl monkey model assessed as cure from parasite infection at 0.098 to 1.56 mg/kg, po qd for 7 days relative to control1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID111807Antimalarial activity against Plasmodium berghei in mice (Mus musculus) by parenteral route and change in mean survival time in days was determined at 320 mg/kg subcutaneous dose; 5 cured at 60 days post infection1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antimalarial and antitumor effects of 2-amino-4-(hydrazino and hydroxyamino)-6-[(aryl)thio]quinazolines.
AID1143940Antimalarial activity against Plasmodium berghei infected in mouse assessed as increase in mean survival days of host at 5 mg/kg, sc administered 72 hrs after infection relative to control1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID1143987Antimalarial activity against sporozoite-induced Plasmodium gallinaceum infected in white leghorn chicken assessed as disease cure from parasite infection at 160 mg/kg, sc administered 72 hrs after infection1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (68.75)18.7374
1990's0 (0.00)18.2507
2000's1 (6.25)29.6817
2010's3 (18.75)24.3611
2020's1 (6.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.30 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]